Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.41 |
| ▸ | CDK4 | P11802 | 4/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.41 |
| ▸ | CCND1 | P24385 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | CCND3 | P30281 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17530508 | 0.84 | FGFR1 (0.50) | FGFR1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL17531001 | 0.82 | HDAC6 (0.42) | FGFR1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL23890222 | 0.82 | FGFR2 (0.41) | FGFR1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL19057623 | 0.82 | FGFR1 (0.46) | FGFR1KDRFGFR2HDAC6HDAC1 | |
| SCHEMBL15796632 | 0.77 | MAP4K1 (0.38) | MAP4K1 | |
| SCHEMBL23890228 | 0.75 | FGFR2 (0.39) | FGFR1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL14659069 | 0.74 | JAK3 (0.47) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL5248615 | 0.73 | KDR (0.44) | FGFR1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL17530926 | 0.72 | FGFR2 (0.62) | FGFR1FGFR2TGFBR1FGFR3 | |
| SCHEMBL31411417 | 0.72 | HTR1A (0.40) | FGFR1CDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| EP-3184521-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016026445-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | 上海海和药物研究开发有限公司 | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885CDK4 25/4885CCNA2 2064/4885 |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885CDK4 25/4885CCNA2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.